Lin Jie, Zhu Hongli, Lu Xuechun, Yang Bo, Han Weidong, Dai Hanren, Wang Yao
Department of Geriatric Hematology, Chinese People's Liberation Army General Hospital, Beijing, China.
Intern Med. 2010;49(21):2341-6. doi: 10.2169/internalmedicine.49.3996. Epub 2010 Nov 1.
Cytokine-induced killer (CIK) cells have been shown to be effective in the treatment of advanced cancer and minimal residual diseases. We report a multiple myeloma (MM) patient with concomitant lung cancer and paraneoplastic dermatoses, who received cellular immunotherapy with CIK cells which were derived from peripheral blood mononuclear cells (PBMCs) after being primed with anti-cluster of differentiation 3 (CD3) monoclonal antibody, interleukin-2 (IL-2), interferon-γ (IFN-γ) and IL-1. After treatment MM and lung cancer remained stable and no progression or recurrence was observed. Paraneoplastic dermatoses were obviously improved after treatment, which was first reported. No evident side effects were observed. These findings suggested that cellular immunotherapy with CIK cells was safe and effective in this patient with MM and lung cancer, and it might be a potent therapeutic option for paraneoplastic dermatoses.
细胞因子诱导的杀伤细胞(CIK)已被证明在治疗晚期癌症和微小残留病方面有效。我们报告了一名伴有肺癌和副肿瘤性皮肤病的多发性骨髓瘤(MM)患者,该患者接受了CIK细胞的细胞免疫治疗,CIK细胞是由外周血单个核细胞(PBMC)在抗分化簇3(CD3)单克隆抗体、白细胞介素-2(IL-2)、干扰素-γ(IFN-γ)和IL-1启动后产生的。治疗后MM和肺癌病情保持稳定,未观察到进展或复发。副肿瘤性皮肤病在治疗后明显改善,这为首例报道。未观察到明显副作用。这些发现表明,CIK细胞的细胞免疫治疗对该MM合并肺癌患者安全有效,且可能是副肿瘤性皮肤病的一种有效治疗选择。